What for patients with NRG1 fusions? Looking into Pandora's box - PubMed
5 hours ago
- #NRG1
- #HER
- #target therapy
- NRG1 is a ligand that interacts with HER2-4 receptors, activating pathways linked to cell survival and proliferation.
- NRG1 gene fusions in some cancers lead to constitutive HER signaling activation, promoting tumorigenesis.
- Targeted therapies for NRG1 fusions include inhibitors of NRG1 or HER3/HER4, offering personalized treatment options.
- Combination therapies with targeted approaches, small compounds, and monoclonal antibodies are being explored for increased efficacy.
- The review covers drugs targeting NRG1/HER deregulation, their chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy in NRG1-positive patients.